Han S, et al. – Given that the prognostic value of CD133 and SOX2 expression in advanced cancer is not fully understood, researchers conducted this study to further examine the link between CD133 or SOX2 positivity and clinical outcomes for patients with advanced cancer. For this purpose, they identified and reviewed 13 relevant studies with 1,358 cases (CD133) and 5 studies with 433 cases (SOX2). They calculated HRs and 95% CIs to assess the relation between CD133 or SOX2 positivity and overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), cancer-specific survival (CSS), or recurrence-free survival (RFS) from multivariable analysis. Overall, they observed a correlation of positive CD133 with worse CSS and OS but no association between CD133 positivity and DFS. Similarly, SOX2 positivity was linked to poor DFS and RFS but not to PFS.